Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report

Jennifer Cable¹, Anthony Fauci², William E Dowling³, Stephan Günther⁴, Dennis A Bente^{5

6}, Pragya Dhruv Yadav⁷, Lawrence C Madoff⁸, Lin-Fa Wang⁹, Rahul K Arora^{10

11}, Maria Van Kerkhove¹², May C Chu¹³, Thomas Jaenisch¹³, Jonathan H Epstein¹⁴, Simon David William Frost¹⁵, Daniel G Bausch¹⁶, Lisa E Hensley^{17

18}, Éric Bergeron¹⁹, Ioannis Sitaras²⁰, Michael D Gunn²¹, Thomas W Geisbert^{22

23}, César Muñoz-Fontela⁴, Florian Krammer²⁴, Emmie de Wit²⁵, Pontus Nordenfelt²⁶, Erica Ollmann Saphire²⁷, Sarah C Gilbert²⁸, Kizzmekia S Corbett²⁹, Luis M Branco³⁰, Sylvain Baize^{31

32

33}, Neeltje van Doremalen²⁵, Marco A Krieger^{34

35}, Sue Ann Costa Clemens^{36

37}, Renske Hesselink³, Dan Hartman³⁸

Affiliations

¹ PhD Science Writer, New York, New York, USA.
² Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
³ Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway.
⁴ Bernhard Nocht Institute for Tropical Medicine and German Center for Infection Research, Hamburg, Germany.
⁵ University of Texas Medical Branch, Galveston National Laboratory, Galveston, Texas, USA.
⁶ Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.
⁷ Indian Council of Medical Research-National Institute of Virology, Pune, India.
⁸ Department of Medicine, University of Massachusetts Chan School of Medicine, Worcester, Massachusetts, USA.
⁹ Duke-NUS Medical School, Singapore.
¹⁰ Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
¹¹ Institute of Biomedical Engineering, University of Oxford, Oxford, UK.
¹² World Health Organization, Geneva, Switzerland.
¹³ Colorado School of Public Health, Anschutz Medical Campus, Aurora, Colorado, USA.
¹⁴ EcoHealth Alliance, New York, New York, USA.
¹⁵ Microsoft Research, Redmond, Washington, USA.
¹⁶ FIND, the global alliance for diagnostics, Geneva, Switzerland.
¹⁷ Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia.
¹⁸ Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
¹⁹ Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
²⁰ W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
²¹ Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
²² University of Manitoba, Winnipeg, Manitoba, Canada.
²³ Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
²⁴ Department of Microbiology and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
²⁵ Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
²⁶ Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.
²⁷ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
²⁸ Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
²⁹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
³⁰ Zalgen Labs, Germantown, Maryland, USA.
³¹ Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.
³² Centre International de Recherche en Infectiologie (CIRI), Lyon, France.
³³ INSERM, Ecole Normale Supérieure de Lyon, Université de Lyon, Lyon, France.
³⁴ Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation - Paraná, Curitiba, Brazil.
³⁵ Integrated Translational Program in Chagas Disease from Fiocruz (Fio-Chagas), Oswaldo Cruz Foundation - Rio de Janeiro, Rio de Janeiro, Brazil.
³⁶ Oxford Vaccine Group, Oxford University, Oxford, UK.
³⁷ Institute for Global Health, University of Siena, Siena, Italy.
³⁸ Bill & Melinda Gates Foundation, Seattle, Washington, USA.

PMID: 36183296
PMCID: PMC9538336
DOI: 10.1111/nyas.14898

Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report

Jennifer Cable et al. Ann N Y Acad Sci. 2022 Dec.

. 2022 Dec;1518(1):209-225.

doi: 10.1111/nyas.14898. Epub 2022 Oct 2.

Authors

Affiliations

¹ PhD Science Writer, New York, New York, USA.
² Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
³ Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway.
⁴ Bernhard Nocht Institute for Tropical Medicine and German Center for Infection Research, Hamburg, Germany.
⁵ University of Texas Medical Branch, Galveston National Laboratory, Galveston, Texas, USA.
⁶ Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.
⁷ Indian Council of Medical Research-National Institute of Virology, Pune, India.
⁸ Department of Medicine, University of Massachusetts Chan School of Medicine, Worcester, Massachusetts, USA.
⁹ Duke-NUS Medical School, Singapore.
¹⁰ Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
¹¹ Institute of Biomedical Engineering, University of Oxford, Oxford, UK.
¹² World Health Organization, Geneva, Switzerland.
¹³ Colorado School of Public Health, Anschutz Medical Campus, Aurora, Colorado, USA.
¹⁴ EcoHealth Alliance, New York, New York, USA.
¹⁵ Microsoft Research, Redmond, Washington, USA.
¹⁶ FIND, the global alliance for diagnostics, Geneva, Switzerland.
¹⁷ Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia.
¹⁸ Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
¹⁹ Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
²⁰ W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
²¹ Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
²² University of Manitoba, Winnipeg, Manitoba, Canada.
²³ Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
²⁴ Department of Microbiology and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
²⁵ Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
²⁶ Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.
²⁷ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
²⁸ Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
²⁹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
³⁰ Zalgen Labs, Germantown, Maryland, USA.
³¹ Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.
³² Centre International de Recherche en Infectiologie (CIRI), Lyon, France.
³³ INSERM, Ecole Normale Supérieure de Lyon, Université de Lyon, Lyon, France.
³⁴ Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation - Paraná, Curitiba, Brazil.
³⁵ Integrated Translational Program in Chagas Disease from Fiocruz (Fio-Chagas), Oswaldo Cruz Foundation - Rio de Janeiro, Rio de Janeiro, Brazil.
³⁶ Oxford Vaccine Group, Oxford University, Oxford, UK.
³⁷ Institute for Global Health, University of Siena, Siena, Italy.
³⁸ Bill & Melinda Gates Foundation, Seattle, Washington, USA.

PMID: 36183296
PMCID: PMC9538336
DOI: 10.1111/nyas.14898

Abstract

The COVID-19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10-13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium "Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases" to discuss the successes and challenges of the COVID-19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID-19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID-19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements-notably, in low-to-middle income countries-must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens.

Keywords: COVID-19; Ebola virus; Lassa virus; Nipah virus; infectious diseases; vaccines; zoonotic diseases.

PubMed Disclaimer

Conflict of interest statement

R.K.A. is a Fellow at Flagship Pioneering. He was previously a Technical Consultant for the Bill and Melinda Gates Foundation Strategic Investment Fund, is a minority shareholder of Alethea Medical, and was a former Senior Policy Advisor at Health Canada; each of these relationships is unrelated to the present work. S.G. owns stock in Vaccitech, a company using ChAdOx1 to develop vaccines, and is named as an inventor on patents covering the ChAdOx1 technology and the ChAdOx1 Covid vaccine.

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS‐CoV‐2 serological assays, NDV‐based SARS‐CoV‐2 vaccines, and influenza virus vaccines, which list Florian Krammer as coinventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS‐CoV‐2. F.K. has consulted for Merck and Pfizer (before 2020) and is currently consulting for Pfizer, Seqirus, 3^rd Rock Ventures, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS‐CoV‐2, has historically collaborated with GSK on influenza virus vaccines, and is currently collaborating with Dynavax on influenza virus vaccine development.

Figures

See this image and copyright information in PMC

References

1. Novel 2019 coronavirus genome ‐ SARS‐CoV‐2 coronavirus . (2020). Virological. https://virological.org/t/novel‐2019‐coronavirus‐genome/319
1. Classification of Omicron (B.1.1.529): SARS‐CoV‐2 Variant of Concern. (2022). https://www.who.int/news/item/26‐11‐2021‐classification‐of‐omicron‐(b.1....
1. National Institutes of Health . NIH launches clinical trials network to test COVID‐19 vaccines and other prevention tools. (2020). https://www.nih.gov/news‐events/news‐releases/nih‐launches‐clinical‐tria...
1. Marston, H. D. , Paules, C. I. , & Fauci, A. S. (2017). The critical role of biomedical research in pandemic preparedness. JAMA, 318, 1757–1758. - PubMed
1. Graham, B. S. , & Corbett, K. S. (2020). Prototype pathogen approach for pandemic preparedness: World on fire. Journal of Clinical Investigation, 130, 3348–3349. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report

Affiliations

Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous